Your browser doesn't support javascript.
loading
Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
Musa, Ahmed M; Mbui, Jane; Mohammed, Rezika; Olobo, Joseph; Ritmeijer, Koert; Alcoba, Gabriel; Muthoni Ouattara, Gina; Egondi, Thaddaeus; Nakanwagi, Prossy; Omollo, Truphosa; Wasunna, Monique; Verrest, Luka; Dorlo, Thomas P C; Musa Younis, Brima; Nour, Ali; Taha Ahmed Elmukashfi, Elmukashfi; Ismail Omer Haroun, Ahmed; Khalil, Eltahir A G; Njenga, Simon; Fikre, Helina; Mekonnen, Tigist; Mersha, Dagnew; Sisay, Kasaye; Sagaki, Patrick; Alvar, Jorge; Solomos, Alexandra; Alves, Fabiana.
Afiliação
  • Musa AM; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
  • Mbui J; Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
  • Mohammed R; Leishmaniasis Research and Treatment Center, University of Gondar, Gondar, Ethiopia.
  • Olobo J; Department of Immunology and Molecular Biology, Leishmaniasis Unit, College of Health Sciences, Makerere University, Kampala, Uganda.
  • Ritmeijer K; Médecins sans Frontières, OCA, Amsterdam, The Netherlands.
  • Alcoba G; Médecins sans Frontières, OCG, Geneva, Switzerland.
  • Muthoni Ouattara G; Drugs for Neglected Diseases Initiative, Nairobi, Kenya.
  • Egondi T; Drugs for Neglected Diseases Initiative, Nairobi, Kenya.
  • Nakanwagi P; Drugs for Neglected Diseases Initiative, Nairobi, Kenya.
  • Omollo T; Drugs for Neglected Diseases Initiative, Nairobi, Kenya.
  • Wasunna M; Drugs for Neglected Diseases Initiative, Nairobi, Kenya.
  • Verrest L; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Dorlo TPC; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Musa Younis B; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
  • Nour A; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
  • Taha Ahmed Elmukashfi E; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
  • Ismail Omer Haroun A; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
  • Khalil EAG; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
  • Njenga S; Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
  • Fikre H; Leishmaniasis Research and Treatment Center, University of Gondar, Gondar, Ethiopia.
  • Mekonnen T; Leishmaniasis Research and Treatment Center, University of Gondar, Gondar, Ethiopia.
  • Mersha D; Médecins sans Frontières, Abdurafi, Ethiopia.
  • Sisay K; Médecins sans Frontières, Abdurafi, Ethiopia.
  • Sagaki P; Amudat Hospital, Amudat Karamoja Sub-region, Uganda.
  • Alvar J; Drugs for Neglected Diseases Initiative, Geneva, Switzerland.
  • Solomos A; Drugs for Neglected Diseases Initiative, Geneva, Switzerland.
  • Alves F; Drugs for Neglected Diseases Initiative, Geneva, Switzerland.
Clin Infect Dis ; 76(3): e1177-e1185, 2023 02 08.
Article em En | MEDLINE | ID: mdl-36164254
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leishmaniose Visceral / Antiprotozoários Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Child / Humans País/Região como assunto: Africa Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leishmaniose Visceral / Antiprotozoários Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Child / Humans País/Região como assunto: Africa Idioma: En Ano de publicação: 2023 Tipo de documento: Article